Home » Archive

Marketwire, News, NYSE:PFE, Syndication »

Lpath Receives First U.S. Patent for Anti-LPA Antibody, Lpathomab

Posted by Mary Canady April 25th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Apr 25, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that it has been issued a key patent prote…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Receives First U.S. Patent for Anti-LPA Antibody, Lpathomab

Posted by Mary Canady April 25th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Apr 25, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that it has been issued a key patent prote…

More...

Marketwire, News, Syndication »

Gene Ray, Founder of $2.6 Billion Titan Corp, Invests in Medistem’s ERC Technology and Joins Advisory Board

Posted by Mary Canady April 25th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Apr 25, 2012) – Medistem Inc. (PINKSHEETS: MEDS) announced Dr. Gene Ray, founder of $2.6 Billion Titan Corp, has invested in and joined the Advisory Board for Medistem Inc. Dr. Ray is a Ph.D in Theoretical Physics, Inven…

More...

Marketwire, News, Syndication »

AstraZeneca to Acquire Ardea Biosciences for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout

Posted by Mary Canady April 22nd, 2012 .
No Comments

SAN DIEGO,CA–(Marketwire – Apr 23, 2012) – AstraZeneca and Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-b…

More...

Marketwire, News, Syndication »

Quidel Receives CLIA Waiver for Its Sofia(TM) Analyzer and Sofia Influenza A+B Fluorescent Immunoassay (FIA)

Posted by Mary Canady April 20th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Apr 20, 2012) – Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cell-based virology assays, announced today that it has received Clinical Laboratory Improvement Amendments …

More...

Marketwire, News, Syndication »

La Jolla Pharmaceutical Company Announces Development Programs for Lead Product, GCS-100

Posted by Mary Canady April 16th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Apr 16, 2012) – La Jolla Pharmaceutical Company (OTCQB: LJPC) (PINKSHEETS: LJPC) today announced initial product development plans for advancing GCS-100, its first-in-class inhibitor of galectin-3.
On January 20, …

More...

Marketwire, News, Syndication »

Quidel to Hold First Quarter 2012 Financial Results Conference Call on April 25, 2012

Posted by Mary Canady April 13th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Apr 13, 2012) – Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, will release first quarter 2012 financial results after market close on Wedn…

More...

Marketwire, News, Syndication »

ISTA Pharmaceuticals, Inc. (ISTA) Investor Lawsuit Against Buyout Announced by Shareholders Foundation

Posted by Mary Canady April 3rd, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Apr 3, 2012) – The Shareholders Foundation, Inc. announces that an investor filed a lawsuit in State Court for current stockholders of ISTA Pharmaceuticals, Inc. (ISTA) against directors of ISTA Pharmaceuticals, Inc. in a…

More...

Marketwire, News, Syndication »

Medistem Collaborates With Loma Linda University on Treatment of Traumatic Brain Injury Using Endometrial Regenerative Cells (ERC)

Posted by Mary Canady April 2nd, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Apr 3, 2012) – Medistem Inc. (PINKSHEETS: MEDS) announced today collaboration with Dr. C.S. Chen, Head of the Division of Oncology and Hematology of Loma Linda University and Dr. Anatol Manaenko, Zhang Neuroscience Resea…

More...

Marketwire, News, Syndication »

Quidel Receives CE Mark for Its Direct Specimen Rapid PCR Test for Toxigenic Clostridium Difficile

Posted by Mary Canady April 2nd, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Apr 2, 2012) – Quidel Corporation (NASDAQ: QDEL) announced today that it received CE mark for the Quidel MolecularT Direct C. difficile Tox A/B assay for the detection of toxigenic Clostridium difficile bacterial DNA. C….

More...